Bradycardia	O
-	O
induced	O
coronary	B-Multi-tissue_structure
angiogenesis	O
is	O
dependent	O
on	O
vascular	O
endothelial	O
growth	O
factor	O
.	O

A	O
marked	O
coronary	B-Multi-tissue_structure
angiogenesis	O
is	O
known	O
to	O
occur	O
with	O
chronic	O
bradycardia	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
an	O
endothelial	B-Cell
cell	I-Cell
mitogen	O
and	O
a	O
major	O
regulator	O
of	O
angiogenesis	O
,	O
is	O
upregulated	O
in	O
response	O
to	O
low	O
heart	B-Organ
rate	O
and	O
consequential	O
increased	O
stroke	O
volume	O
.	O

Bradycardia	O
was	O
induced	O
in	O
rats	O
by	O
administering	O
the	O
bradycardic	O
drug	O
alinidine	O
(	O
3	O
mg	O
/	O
kg	O
body	B-Organism_subdivision
weight	O
)	O
twice	O
daily	O
.	O

Heart	B-Organ
rate	O
decreased	O
by	O
32	O
%	O
for	O
20	O
to	O
40	O
minutes	O
after	O
injection	O
and	O
was	O
chronically	O
reduced	O
by	O
10	O
%	O
,	O
14	O
%	O
,	O
and	O
18	O
.	O
5	O
%	O
after	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
of	O
treatment	O
,	O
respectively	O
.	O

Arterial	B-Multi-tissue_structure
pressure	O
and	O
cardiac	B-Organ
output	O
were	O
unchanged	O
.	O

Left	B-Tissue
ventricular	I-Tissue
capillary	I-Tissue
length	O
density	O
(	O
mm	O
/	O
mm	O
(	O
3	O
)	O
)	O
increased	O
gradually	O
with	O
alinidine	O
administration	O
;	O
a	O
15	O
%	O
increase	O
after	O
2	O
weeks	O
and	O
a	O
40	O
%	O
increase	O
after	O
3	O
weeks	O
of	O
alinidine	O
treatment	O
were	O
documented	O
.	O

Left	B-Multi-tissue_structure
ventricular	I-Multi-tissue_structure
weight	O
,	O
body	B-Organism_subdivision
weight	O
,	O
and	O
their	O
ratio	O
were	O
not	O
significantly	O
altered	O
by	O
alinidine	O
treatment	O
.	O

After	O
1	O
week	O
of	O
treatment	O
,	O
before	O
an	O
increase	O
in	O
capillary	B-Tissue
length	O
density	O
,	O
VEGF	O
mRNA	O
increased	O
greater	O
than	O
2	O
-	O
fold	O
and	O
then	O
declined	O
to	O
control	O
levels	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

VEGF	O
protein	O
was	O
higher	O
in	O
alinidine	O
-	O
treated	O
rats	O
than	O
in	O
controls	O
after	O
2	O
weeks	O
and	O
increased	O
further	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

Injection	O
of	O
VEGF	O
-	O
neutralizing	O
antibodies	O
over	O
a	O
2	O
-	O
week	O
period	O
completely	O
blocked	O
alinidine	O
-	O
stimulated	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
bFGF	O
mRNA	O
was	O
not	O
altered	O
by	O
alinidine	O
treatment	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
key	O
role	O
in	O
the	O
angiogenic	O
response	O
that	O
occurs	O
with	O
chronic	O
bradycardia	O
.	O

The	O
mechanism	O
underlying	O
this	O
VEGF	O
-	O
associated	O
angiogenesis	O
may	O
be	O
an	O
increase	O
in	O
stretch	O
due	O
to	O
enhanced	O
diastolic	O
filling	O
.	O

